Effect of Peri-Urethral Stimulation on Intra-Urethral Pressure
Study Details
Study Description
Brief Summary
The purpose of this early feasibility prospective study is to gain initial understanding of the effect of acute peri-urethral neurostimulation on the perineal nerves on intra-urethral pressure.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
In this study intra-urethral pressure data will be collected and analyzed with and without peri-urethral neurostimulation. This is a single arm feasibility study of women diagnosed with stress urinary incontinence. The data collected may help researchers have a better understanding of the effect, if any, on neurostimulation on stress or mixed urinary incontinence. After informed consent and all eligibility criteria are met, enrolled participants will be brought in for a stimulation visit. At the stimulation visit, participants will undergo urodynamic testing with and without stimulation. A prophylactic antibiotic will be given before the procedure and a local anesthetic cream will be applied topically to the peri-urethral area. The participant will be prepped for urodynamic testing per protocol. Commercially available simulation needles and external neurostimulator device will be used to perform peri-urethral neurostimulation of the perineal branch of the pudendal nerve. The amplitude will gradually be increased and intra-urethral pressure will be recorded. Stimulation parameters such as amplitude, pulse-width, and frequency will be explored to assess their effect on urethral pressure. Amplitude progressively will be increased until discomfort is noted, no further pressure increases are observed, or maximum output is achieved. When a consistent pressure is observed, record intra-urethral pressure measurements with stimulation on and off. Next, Leak Point Pressure (LPP) testing with and without stimulation will be completed. Start the urodynamic saline infusion until desired volume is reached. Observe for urinary leakage. This will be repeated with the stimulation on.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Urodynamic testing and LLP with and without pudendal nerve stimulation Commercially available stimulation needles will be inserted into the peri-urethral space targeting the perineal branch of the pudendal nerve. An external neurostimulator settings will be adjusted to deliver acute stimulation. Urodynamic testing will be completed by filling the bladder to a set volume and observing for urinary leakage. The assessment will be completed with stimulation turned on and off. The neurostimulator device settings will be adjusted by the investigator to stay within safe and comfortable levels for each individual study participant. |
Diagnostic Test: Urodynamic testing with and without pudendal nerve stimulation
A urodynamic test with and without neurostimulation will be conducted. The external neurostimulator device settings will be adjusted to deliver acute nerve stimulation per the individual tolerance level to assess the effect on urethral pressure. A leak point pressure (LLP) during Valsalva maneuver will be assessed with and without acute nerve stimulation.
|
Outcome Measures
Primary Outcome Measures
- The effect of acute peri-urethral neurostimulation on intra-urethral pressure. [At stimulation visit, 1 day]
Intra-urethral pressure (measured in cmH2O) will be recorded with stimulation on and off.
Secondary Outcome Measures
- Safety and tolerability will be assessed in relation to the incidence of adverse events [One week after completing the stimulation visit]
Safety and tolerability of peri-urethral stimulation will be assessed in related to the incidence of adverse events reported.
- Valsalva leak point pressure (LLP) in response to acute peri-urethral neurostimulation compared to no stimulation [At stimulation visit, 1 day]
Leak point pressure (measured in cmH20) will be collected during neurostimulation and without neurostimulation.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Female aged 18 years old or older
-
Capable of understanding the clinical study procedures and giving informed consent
-
Willing and able to undergo the study procedure
-
Diagnosis of SUI or stress predominant mixed incontinence, for at least 6 months
-
Provided authorization to use and disclose information for research purposes
Exclusion Criteria:
-
Predominant urge incontinence per patient report or medical record
-
Previously diagnosed with Interstitial Cystitis
-
Active symptomatic uncontrolled bladder instability as determined by the investigator
-
Regularly or intermittently used a urethral catheter
-
Active bladder cancer (currently undergoing or scheduled to undergo treatment for bladder cancer).
-
Previous radiation treatment in the pelvic floor
-
Three or more culture-proven bacterial UTIs in the last 12 months
-
History or symptoms of cystocele, enterocele or rectocele of grade 3 or 4. Per the medical record or as determined by the investigator
-
Current infection (urethritis, cystitis or vaginitis) as determined by investigator.
-
Active herpes genitalis
-
Unevaluated hematuria
-
BMI ≥ 35
-
Currently taking, or has taken within 4 weeks prior to the screening/baseline visit, pharmacological treatment for SUI (including but not limited to, alpha adrenergics, and tricyclic antidepressants)
-
Severe or uncontrolled diabetes, (defined as being a diabetic with a hemoglobin A1c of ≥10%) per patient medical record.
-
History of drug/alcohol abuse, mental dysfunction, or other factors limiting her ability to cooperate fully
-
Pregnancy test with positive result during screening or women who are breastfeeding
-
Women who are pregnant and/or have given birth in the previous 12 months
-
Have implanted neurostimulators, pacemakers, or defibrillators
-
Known systemic neurological dysfunctions
-
Severe coagulation disorders
-
Medically unstable at time of study and unsafe to undergo urodynamic testing as determined by the investigator
-
Presence of an artificial urinary sphincter
-
Any medical condition (e.g. Multiple Sclerosis, spinal cord injury, mobility) or uncontrolled chronic disease (e.g. renal diseases that requires dialysis) that would interfere with the patient's ability to comply with the protocol and/or may affect the outcome of this study or safety of the subject as determined by the investigator
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Beaumont Hospital-Royal Oak | Royal Oak | Michigan | United States | 48073 |
Sponsors and Collaborators
- William Beaumont Hospitals
Investigators
- Principal Investigator: Kenneth Peters, MD, William Beaumont Hospitals
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2023-117